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Two recent studies identified loss-of-function mutations in the histone H3 methyltransferase EZH2 in
myelodysplastic syndromes andmyeloproliferative neoplasms, provided further demonstration of mutations
in epigenetic modifiers in myeloid malignancies, and suggest EZH2 functions as a tumor-suppressor gene in
these malignancies rather than an oncogene as in some other malignancies.Laboratory studies have implicated epi-
genetic dysregulation as a common path-
ogenetic mechanism in myelodysplastic
syndromes (MDS), myeloproliferative
neoplasms (MPNs), and acute myeloid
leukemia (AML). Notably, genome-wide
methylation studies have identified a set
of genes recurrently targeted by aberrant
promoter hypermethylation in AML (Fig-
ueroa et al., 2010). Recent studies have
shown that chromosome translocations
involving MLL and JARID1A found in
myeloid malignancies result in dysregula-
tion of chromatin state and resultant
activation of genes that contribute to
leukemogenesis (Krivtsov et al., 2008;
Wang et al., 2009). In addition, hypome-
thylating agents (5-azacytidine and deci-
tabine) are approved for the treatment
MDS and AML, illustrating the therapeutic
relevance of epigenetic alterations in
myeloid malignancies. However, until re-
cently, somatic mutations that directly
dysregulate the epigenetic state of
leukemic cells but are not chromosomal
rearrangements had not been reported.
Two groups led by Nicholas Cross and
Joop Jansen recently reported identifica-tion of recurrent somatic EZH2 mutations
in MDS, MPNs, and MDS/MPN overlap
disorders (Ernst et al., 2010; Nikoloski
et al., 2010). Alterations in the long arm
of chromosome 7 are common in MDS
and AML and are associated with adverse
outcome of these patients. Both groups
first used high-resolution SNP arrays to
characterize regions of acquired unipa-
rental disomy (aUPD) and microdeletions
involving chromosomal locus 7q36, which
includes the EZH2 gene. They then per-
formed gene resequencing of EZH2 and
identified somatic frameshift, nonsense,
and missense mutations in MDS, MDS/
MPN, and MPN, with and without con-
comitant chromosome 7 alterations. The
identified missense mutations most com-
monly affected the CXC-SET domain,
which is required for histone methyltrans-
ferase activity, or domain II, which is
necessary for binding to SUZ12, of
EZH2. Importantly, they did not identify
EZH2 mutations in AML with chromo-
some 7 abnormalities, including those
with chromosome 7 aUPD. These results
suggest the existence of an additional,
not yet identified, tumor suppressorgene for MDS, MPN, and AML on chro-
mosome 7. This is consistent with pre-
vious cytogenetic studies of chromosome
7 deletions in MDS and AML that have
delineated several regions of common
deletion on chromosome 7, only one of
which includes the EZH2 locus (Le Beau
et al., 1996). In addition, both current
studies suggest that patients having
MDS with EZH2 mutations have wors-
ened overall survival compared to those
having MDS without EZH2 mutations,
independent of the presence or absence
of cytogenetic abnormalities involving
chromosome 7.
The genetic data implicating EZH2 in
the pathogenesis ofmyeloidmalignancies
is in contrast to that observed in other
malignancies. A recent study employed
whole transcriptome resequencing to
identify somatic EZH2 mutations in lym-
phoma and found that all mutations
affected a specific residue within the
EZH2 SET domain, tyrosine 641 (Morin
et al., 2010). However, tyrosine 641 was
not identified as a mutational hotspot in
MDS and MPN by Cross, Jansen, and
colleagues. Moreover, previous studies, August 17, 2010 ª2010 Elsevier Inc. 105
Figure 1. SimpleMutations andChromosomal Translocations in the EpigeneticMachinery in
Myeloid Malignancies
(A) Somatic mutations that affect the epigenetic machinery include gain-of-function mutations in JAK2
(which can phosphorylate histone 3 tyrosine 41) and loss-of-function mutations in the H3K27 demethylase
UTX, in the H3K27 methyltransferase EZH2, and in the methyl-hydoxylase TET2.
(B) Chromosomal translocations that affect the epigenetic machinery include MLL fusions that loss H3K4
methyltransferase and gain H3K79methyltransferase activity, JARID1A/PHF23 fusions that regulate H3K4
di/tri-methylation, and a spectrum of leukemogenic fusions (including PML-RARA, core binding factor
fusions, and MOZ/MORF fusions) that interact with histone deacetylases and influence chromatin state.
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prostate and breast carcinomas and that
EZH2 overexpression is associated with
metastatic progression of epithelial malig-
nancies (Varambally et al., 2002). Taken
together, the genetic data suggest that
EZH2 can function as an oncogene or a
tumor suppressor gene in different onco-
genic contexts, a hypothesis that requires
investigation in subsequent functional
studies. The contradicting effects of EZH2
in different tissues is of immediate thera-
peutic relevance, because inhibition of
EZH2 is being investigated as a potential
therapy for hematopoietic and epithelial
malignancies but inhibition of EZH2 might
enhance malignant transformation in
some tissues.106 Cancer Cell 18, August 17, 2010 ª2010 EAn important question is how inactivat-
ing mutations in EZH2 contribute to he-
matopoietic transformation. EZH2 is a
histone H3 lysine 27 (H3K27) methytrans-
ferase, and the H3K27 trimethyl mark
placed by EZH2 is associated with tran-
scriptional repression. Cross and col-
leagues demonstrated that MDS/MPN-
associated EZH2 mutant proteins had
markedly reduced methyltransferase
activity. Although these studies demon-
strate that EZH2 mutations are loss of
function with respect to H3K27 methyl-
transferase activity, the mechanism by
which loss of EZH2 contributes to hema-
topoietic transformation has not been
established. By contrast, overexpression
of EZH2 in epithelial malignancies is asso-lsevier Inc.ciated with transcriptional repression of
a discrete set of genes including INK4B-
ARF-INK4A, E-cadherin, p57, and p27
(Varambally et al., 2002). It will therefore
be important in subsequent studies to
use genome-wide techniques, including
microarray and chromatin immunoprecip-
itation sequencing (ChIP-seq), to investi-
gate gene expression and chromatin state
in EZH2 wild-type and mutant cells to
delineate whether inactivating EZH2
mutations contribute to hematopoietic
transformation through alterations in
chromatin state at specific target genes.
Previous work demonstrated that condi-
tional inactivation of Ezh2 in the mouse
hematopoietic system results in defective
B lymphocyte development without de-
monstrable effects on normal myelopoie-
sis (Su et al., 2003). It will therefore be
important to better delineate the effects
of EZH2 loss on hematopoietic stem/pro-
genitor function and to develop models of
MPN/MDS by combining Ezh2 loss with
other somatic alterations found in EZH2-
mutant MPN/MDS patient samples.
Notably, previous studies have shown
that EZH2 physically interacts with DNA
methyltransferases and that H3K27
trimethylation is a prerequisite for DNA
promoter methylation (Vire et al., 2006).
Previous studies have identified alterations
in DNA promoter methylation in patients
with MDS and AML. In addition, although
DNA hypomethylating agents have de-
monstrated significant efficacy in MDS
and AML patients, to date no studies
have identified genetic or epigenetic alter-
ations that predict for response, or lack of
response, to these agents. Subsequent
studies will therefore need to correlate
EZH2 mutational analysis with genome-
wide studies of DNA methylation to deter-
minewhetherEZH2 loss inMPN/MDScells
is associated with changes inmethylation-
mediated regulation of gene expression,
and whether EZH2 mutational status
influences the likelihood of response to
epigenetically targeted therapies.
The current studies clearly indicate that
inactivation of EZH2 contributes to the
pathogenesis of myeloid malignancies.
This work, and other recent studies re-
porting mutations in the H3K27 demethy-
lase UTX and in TET2, a putative effector
of DNA methylation, demonstrates that
somatic mutations which dysregulate the
epigenetic machinery are common in
myeloid malignancies. It is likely that
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Previewsalterations in the epigenetic state in
myeloid malignancies can occur via
distinct mechanisms (Figure 1). In some
cases, somatic mutations that alter
proteins that modify chromatin and meth-
ylate/demethylate DNA may result in
epigenetically mediated changes in target
gene expression (Figure 1A). In other
cases, chromosomal translocations result
in alterations in the activity of chromatin-
modifying enzymes, which can directly
target effectors of hematopoietic transfor-
mation (Figure 1B). It is also likely that
there are heretofore-undefined mecha-
nisms that contribute to changes in the
epigenome in leukemic cells. Further
studies that integrate mutational data
with studies of chromatin modifications,
DNA methylation, and gene expression
will be crucial, and future studies probably
will identify additional mutations in the
epigenetic framework in leukemias and
in other hematopoietic and nonhemato-poietic neoplasms. Such work in combi-
nation with disease-specific in vivo
models will hopefully uncover the actual
biologic consequences of such newly
identified mutations in epigenetic modi-
fiers on malignant pathogenesis.REFERENCES
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